GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » MedTech Acquisition Corp (NAS:MTACU) » Definitions » PE Ratio (TTM)

MTACU (MedTech Acquisition) PE Ratio (TTM) : N/A (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is MedTech Acquisition PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-15), MedTech Acquisition's share price is $11.35. MedTech Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, MedTech Acquisition's PE Ratio (TTM) for today is N/A.


The historical rank and industry rank for MedTech Acquisition's PE Ratio (TTM) or its related term are showing as below:

MTACU' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: 201.89
Current: At Loss


During the past 3 years, the highest PE Ratio (TTM) of MedTech Acquisition was 201.89. The lowest was 0.00. And the median was 0.00.


MTACU's PE Ratio (TTM) is not ranked
in the Diversified Financial Services industry.
Industry Median: 45.56 vs MTACU: At Loss

MedTech Acquisition's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

As of today (2024-12-15), MedTech Acquisition's share price is $11.35. MedTech Acquisition's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00. Therefore, MedTech Acquisition's PE Ratio without NRI for today is N/A.

During the past 3 years, MedTech Acquisition's highest PE Ratio without NRI was 201.89. The lowest was 0.00. And the median was 0.00.

MedTech Acquisition's EPS without NRI for the three months ended in Jun. 2023 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.

MedTech Acquisition's EPS (Basic) for the three months ended in Jun. 2023 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00.


MedTech Acquisition PE Ratio (TTM) Historical Data

The historical data trend for MedTech Acquisition's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedTech Acquisition PE Ratio (TTM) Chart

MedTech Acquisition Annual Data
Trend Dec20 Dec21 Dec22
PE Ratio (TTM)
N/A 65.87 52.79

MedTech Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.77 35.34 52.79 192.45 At Loss

Competitive Comparison of MedTech Acquisition's PE Ratio (TTM)

For the Shell Companies subindustry, MedTech Acquisition's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedTech Acquisition's PE Ratio (TTM) Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where MedTech Acquisition's PE Ratio (TTM) falls into.



MedTech Acquisition PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

MedTech Acquisition's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=11.35/0.000
=N/A

MedTech Acquisition's Share Price of today is $11.35.
MedTech Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


MedTech Acquisition  (NAS:MTACU) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


MedTech Acquisition PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of MedTech Acquisition's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


MedTech Acquisition Business Description

Traded in Other Exchanges
N/A
Address
48 Maple Avenue, Greenwich, CT, USA, 06830
Website
MedTech Acquisition Corp is a blank check company.
Executives
Magnetar Financial Llc 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Magnetar Capital Partners Lp 10 percent owner 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201
Supernova Management Llc 10 percent owner 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David J. Snyderman 10 percent owner C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201
David L Treadwell director 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102
Manuel Aguero director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Thierry B. Thaure director 3957 POINT EDEN WAY, HAYWARD CA 94545
David J Matlin director, 10 percent owner, officer: Chief Financial Officer
Karim Karti director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Christopher C Dewey director, 10 percent owner, officer: Chief Executive Officer 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Robert H. Weiss officer: Chief Admin Officer and Sec. 585 WEED STREET, NEW CANAAN CT 06840
Maurice R Ferre director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317
Ivan Delevic director C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317
Medtech Acquisition Sponsor Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Martin William Roche director 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022